Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05066230 is registered in ClinicalTrials.gov with Kodiak Sciences Inc as lead sponsor.

NCT NCT05066230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Lead sponsor
Kodiak Sciences Inc
Phase
Phase 3
Overall status
Terminated
Start date
September 7, 2021
Completion date
August 31, 2023
Enrollment
253 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy